Frontlight ResearchEarly access
Taking peoplePhase 2
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Burkina Faso, Côte d’Ivoire, Gabon, Ghana, Kenya, Rwanda, and Uganda13 sites in 7 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 12 Feb 2026
- Expected to end
- 18 Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- KAE609
- SoC (Coartem)
- KLU156
- Record updated
- 15 October 2026
Who can take part
- Age
- 2 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Male and female participants 2 to <12 years of age at screening
- Participants must have acute uncomplicated P. falciparum malaria mono infection at screening confirmed by a parasite count between 1,000 to 150,000 asexual parasite count/μl of blood for P. falciparum
- Participants must weigh at least 10 kg at screening
Who cannot take part
- Participants with signs and symptoms of severe/complicated malaria at screening or mixed Plasmodium infection (i.e., infection with more than one malaria species) at screening
- Any known/suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection at screening
- Moderate to severe anemia, chronic hemoglobinopathy (Hemoglobin level < 8 g/dL), or known chronic underlying disease such as sickle cell disease at screening
- Known clinically significant liver disease (e.g., chronic hepatitis, liver cirrhosis (compensated or decompensated), history of hepatitis B or C, hepatitis A or B vaccination in the last 3 months, known gallbladder or bile duct disease, acute or chronic pancreatitis. Clinical or laboratory evidence of any of the following at screening:; AST/ALT > 3 x the upper limit of normal range (ULN), regardless of the level of total bilirubin; AST/ALT > 1.5 and ≤ 2 x ULN and total bilirubin is > ULN; Total bilirubin > 2 x ULN, regardless of the level of AST/ALT
- History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study such as:; Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker; History of familial long QT syndrome or known family history of Torsades de Pointe; Resting heart rate (physical exam or 12 lead ECG) < 50 bpm; Other protocol-defined inclusion/exclusion criteria may apply
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 12 years old?
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
The 2 groups in the trial
- Cohort C2: KLU156 + KAE609Treatment being tested
KLU156 + KAE609 was administered orally with light meal.
Treatment: KAE609 and KLU156
- Cohort C2: SoC (Artemether + lumefantrine)Existing treatment, for comparison
Artemether + lumefantrine was administered orally as per label.
Treatment: SoC (Coartem)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria
- Criteria questions
- Built from NCT07811908, who can take part
- Record updated
- 15 October 2026